Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05765812 Phase 1, Phase 2
Recruiting
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult P...
Condition
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Enrollment
116 pts
Location
United States, Spain, Switzerland
Sponsor
Debiopharm International SA
NCT07487363 Phase 1, Phase 2
Recruiting
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ...
Condition
Atherosclerotic Cardiovascular Diseases
Enrollment
80 pts
Location
China
Sponsor
Hudson Biotech
NCT06926075 Phase 1, Phase 2
Recruiting
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Condition
Prostate Cancers
Enrollment
80 pts
Location
Australia
Sponsor
Filamon LTD
NCT06457919 Phase 1, Phase 2
Recruiting
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in Pe...
Condition
Prostate Cancer
Enrollment
50 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT07463807 Phase 1, Phase 2
Recruiting
Testing the Investigational Medication Combination of Teclistamab and Pomalidomi...
Condition
Recurrent Multiple Myeloma
Enrollment
162 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07293754 Phase 1, Phase 2
Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Condition
Advanced Malignant Solid Tumor
Enrollment
150 pts
Location
United States, Ireland, Portugal
Sponsor
Repertoire Immune Medicines
NCT06974812 Phase 1, Phase 2
Recruiting
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid T...
Condition
Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment
250 pts
Location
China
Sponsor
Innovent Biologics (Suzhou) Co
NCT06977737 Phase 1, Phase 2
Recruiting
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Condition
Solid Tumor, Adult
Enrollment
72 pts
Location
Spain, United Kingdom
Sponsor
Accession Therapeutics Limited
NCT06921837 Phase 1, Phase 2
Recruiting
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and ...
Condition
Gastric Cancer Adenocarcinoma Metastatic
Enrollment
122 pts
Location
Australia, South Korea, Taiwan
Sponsor
Bolt Biotherapeutics, Inc.
NCT06535412 Phase 1, Phase 2
Recruiting
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Condition
Systemic Lupus Erythematosus
Enrollment
218 pts
Location
China
Sponsor
ImmuneCare Biopharmaceuticals
NCT06826859 Phase 1, Phase 2
Recruiting
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
Condition
Preterm Birth
Enrollment
400 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT05867251 Phase 1, Phase 2
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
430 pts
Location
United States, Australia
Sponsor
Avenzo Therapeutics, Inc.
NCT04683653 Phase 1, Phase 2
Recruiting
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Condition
Endometrial Cancer
Enrollment
100 pts
Location
United States
Sponsor
University of Chicago
NCT06825494 Phase 1, Phase 2
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
194 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
NCT07276373 Phase 1, Phase 2
Recruiting
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced...
Condition
Neoplasms
Enrollment
50 pts
Location
United States
Sponsor
Corcept Therapeutics
NCT04746183 Phase 1, Phase 2
Recruiting
AGILE (Early Phase Platform Trial for COVID-19)
Condition
Covid19
Enrollment
600 pts
Location
South Africa, United Kingdom
Sponsor
University of Liverpool
NCT04219254 Phase 1, Phase 2
Recruiting
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced S...
Condition
Solid Tumor, Adult
Enrollment
197 pts
Location
United States, Georgia, Germany
Sponsor
BioInvent International AB
NCT04752722 Phase 1, Phase 2
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incom...
Condition
Superficial Bladder Cancer
Enrollment
350 pts
Location
United States, Australia, Canada
Sponsor
enGene, Inc.
NCT07227025 Phase 1, Phase 2
Recruiting
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With M...
Condition
Carcinoma, Non-Small-Cell Lung
Enrollment
60 pts
Location
United States, Canada, China
Sponsor
Janssen Research & Development
NCT04113382 Phase 1, Phase 2
Recruiting
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
Condition
Bowel Preparation
Enrollment
39 pts
Location
United States
Sponsor
Ferring Pharmaceuticals
NCT06555068 Phase 1, Phase 2
Recruiting
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Canc...
Condition
Advanced Unresectable or Metastatic Breast Cancer
Enrollment
528 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co.,
NCT05681650 Phase 1, Phase 2
Recruiting
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Condition
HER2 Positive Advanced Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT06158620 Phase 1, Phase 2
Recruiting
Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Uretero...
Condition
Post Operative Pain
Enrollment
80 pts
Location
United States
Sponsor
University of Texas Southweste
NCT06002659 Phase 1, Phase 2
Recruiting
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Condition
B-cell Lymphoma
Enrollment
18 pts
Location
Sweden
Sponsor
Uppsala University
NCT07258979 Phase 1, Phase 2
Recruiting
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin i...
Condition
Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment
202 pts
Location
China
Sponsor
MediLink Therapeutics (Suzhou)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology